Drug Repurposing of Generic Drugs : Challenges and the Potential Role for Government
© 2023. The Author(s)..
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it 'on label'. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Applied health economics and health policy - 21(2023), 6 vom: 22. Nov., Seite 831-840 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van der Pol, Karel H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.11.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40258-023-00816-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359001912 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359001912 | ||
| 003 | DE-627 | ||
| 005 | 20231226075933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40258-023-00816-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359001912 | ||
| 035 | |a (NLM)37398987 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van der Pol, Karel H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Repurposing of Generic Drugs |b Challenges and the Potential Role for Government |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it 'on label'. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Drugs, Generic |2 NLM | |
| 700 | 1 | |a Aljofan, Mohamad |e verfasserin |4 aut | |
| 700 | 1 | |a Blin, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Cornel, Jan H |e verfasserin |4 aut | |
| 700 | 1 | |a Rongen, Gerard A |e verfasserin |4 aut | |
| 700 | 1 | |a Woestelandt, Aurélie-Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Spedding, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied health economics and health policy |d 2002 |g 21(2023), 6 vom: 22. Nov., Seite 831-840 |w (DE-627)NLM143364413 |x 1179-1896 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:6 |g day:22 |g month:11 |g pages:831-840 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40258-023-00816-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 6 |b 22 |c 11 |h 831-840 | ||